INTRODUCTION {#s1}
============

Forkhead Box M1 (FOXM1), a transcription factor of the forkhead family, is well demonstrated to be critical for proliferation, apoptosis, migration and invasion of human cancer \[[@R1]\]. FOXM1 is also linked to angiogenesis, cellular senescence, DNA damage response, drug resistance, cancer stem cell renewal and differentiation of cancer \[[@R2]\]. Recent study demonstrate the genic overexpression of FOXM1 is a major predictor of adverse outcomes across 39 human malignancies by a computational analysis of FOXM1 expression in mRNA level \[[@R3]\]. Some studies have demonstrated FOXM1-targeted therapy could effectively restrain tumor development of cancer \[[@R4]--[@R7]\]. These evidences suggest FOXM1 may be an attractive prognostic prediction biomarker and therapeutic target for human cancers. However, the prognostic value of FOXM1-protein in human solid tumors is still controversial.

A plenty of studies showed that elevated FOXM1 expression in tumor tissue was correlated with poor survival of patients with various solid tumors such as angiosarcoma \[[@R8]\], breast cancer \[[@R9]\], cervical cancer \[[@R10]\], colorectal cancer \[[@R11]--[@R13]\], gastric cancer \[[@R14]--[@R16]\], hepatic cancer \[[@R17], [@R18]\], laryngeal squamous cell cancer \[[@R19]\], lung cancer \[[@R20]--[@R22]\], malignant peripheral nerve sheath tumor \[[@R23]\], medulloblastoma \[[@R24]\], esophageal cancer \[[@R25]\], ovarian cancer \[[@R26], [@R27]\], pancreatic cancer \[[@R28], [@R29]\] and renal cell cancer \[[@R30]\]. However, other study showed there is no significantly correlation between FOXM1 expression in tumor tissue and outcome of patients with esophageal cancer \[[@R31]\].

Therefore, we carried out a meta-analysis combining available evidences to evaluate the prognostic value of FOXM1 expression in solid tumors. We also evaluated whether the correlation between FOXM1 expression and outcome of patients is different between tumor types. This meta-analysis intended to assess the role of FOXM1 in relation to survival in solid tumors, thereby shed more light on the development of FOXM1-targeted therapy and prognostic prediction in solid tumor.

RESULTS {#s2}
=======

Search results and study characteristics {#s2_1}
----------------------------------------

Twenty-three studies with a total of 2847 patients were included (Figure [1](#F1){ref-type="fig"}). Three evaluated gastric cancer \[[@R14]--[@R16]\], three evaluated lung cancer \[[@R20]--[@R22]\], two studies evaluated colorectal cancer \[[@R11], [@R12]\], two evaluated hepatocellular cancer \[[@R17], [@R18]\], two evaluated esophageal cancer \[[@R25], [@R31]\], two evaluated ovarian cancer \[[@R26], [@R27]\], two evaluated pancreatic cancer \[[@R28], [@R29]\], one evaluated breast cancer \[[@R9]\], angiosarcoma \[[@R8]\], cervical cancer \[[@R10]\], laryngeal squamous cell cancer \[[@R19]\], malignant peripheral nerve sheath tumor \[[@R23]\], medulloblastoma \[[@R24]\] and renal cell cancer \[[@R30]\] respectively. For the region, 20 studies were conducted in Asia, 2 studies in Europe, 1 studies in America.

![Flow diagram of study selection\
FOXM1: Forkhead Box M1.](oncotarget-08-32298-g001){#F1}

Evaluation and expression of FOXM1 {#s2_2}
----------------------------------

The major information of included studies and extracted data from the included studies were summarized in Table [1](#T1){ref-type="table"}. All studies detected FOXM1 expression by IHC. There are seventeen studies used antibody of FOXM1 with clone sc-502, one study used clone K-19 and four studies did not report the antibody clone. The mean of FOXM1 positive patients in solid tumors was 56.71%, range from 25% to 78.64%.

###### Characteristics of studies included in the meta-analysis

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Ref                              PMID       Type of tumor                             Patient No.   Age, median (range)   Male/\   Stage   FOXM1 (+/−) NO.   3-year OS (+/−)%   5-year OS (+/−)%   10-year OS (+/−)%   NOS Score
                                                                                                                            Female                                                                                       
  -------------------------------- ---------- ----------------------------------------- ------------- --------------------- -------- ------- ----------------- ------------------ ------------------ ------------------- -----------
  Bektas, N., et al. (2008)        18254960   Breast cancer                             204           56(25-82)             NR       I-III   146/56            80.84/90.92        68.57/80           53.46/67.3          8

  Chu, X.-Y., et al. (2012)        22326401   Colorectal cancer                         112           NR                    36/76    I-IV    57/55             44.64/63.73        44.64/55.36        NR                  7

  He, S.-y., et al. (2012)         22943878   Cervical cancer                           102           43.55(26-72)          0/102    I-II    75/27             63.33/82.22        54.07/82.22        NR                  8

  Hu, C.-J., et al. (2015)         25482013   Gastric cancer                            40            NR                    28/12    I-IV    26/14             44.32/62.37        NR                 NR                  6

  Hui, M. K. C., et al. (2012)-C   21976009   Oesophageal cancer                        64            NR                    47/17    I-IV    27/37             18.5/18.5          9/18.5             NR                  6

  Hui, M. K. C., et al. (2012)-N   21976009   Oesophageal cancer                        64            NR                    47/17    I-IV    16/48             15.98/19.07        15.98/12.89        NR                  6

  Ito, T., et al. (2016)           27162541   Angiosarcoma                              107           66.3                  63/44    I-IV    28/66             35.34/65.97        23.82/47.12        0/37.7              8

  Jiang, L.-Z., et al. (2011)      21334713   Laryngeal squamous cell carcinoma         89            59(33-85)             78/11    I-IV    49/40             76.33/89.61        57.97/77.78        NR                  8

  Kong, F.-F., et al. (2014)       24715097   Lung cancer                               68            59.44                 38/30    I-IV    43/25             36.53/72.02        11.9/63.05         NR                  7

  Li, D., et al. (2013)            23136192   Colorectal cancer                         203           NR                    86/117   I-IV    132/71            80.31/92.91        49.6/85.9          NR                  6

  Li, X., et al. (2014)            23873251   Gastric cancer                            103           NR                    68/35    I-IV    81/22             55.34/77.12        35.73/63.4         NR                  8

  Ning, Z., et al. (2014)          24993031   Pancreatic ductal adenocarcinoma          136           67(34-80)             74/62    II      86/50             29.33/39.00        10.56/26.1         2.64/23.46          8

  Okada, K., et al. (2013)         23054116   Gastric cancer                            77            NR                    52/25    NR      53/24             70.2/90.26         59.6/90.26         NR                  7

  Priller, M., et al. (2011)       21918172   Medulloblastoma                           41            NR                    22/19    NR      20/21             42.98/90.73        42.98/85.11        22.75/84.83         6

  Sun, H.-C., et al. (2011)        21431285   Hepatocellular cancer                     151           NR                    130/20   I-III   89/61             32.76/76.85        32.76/64.29        NR                  8

  Takata, A., et al. (2014)        24778055   Oesophageal cancer                        174           64(46-81)             155/19   I-IV    94/80             44.16/67.51        42.39/64.47        36.8/61.68          8

  Wen, N., et al. (2014)           24885308   Ovarian cancer                            158           53(26-79)             0/158    I-IV    101/57            44.37/68.49        13.83/41.16        NR                  8

  Wu, X.-R., et al. (2013)         23263830   Renal cell cancer                         87            56.6(24-82)           60/27    NR      37/50             69.66/95.21        69.66/79.04        NR                  8

  Xia, J.-T., et al. (2012)        22249132   Pancreatic ductal adenocarcinoma          80            59(28-78)             48/32    I-IV    53/27             0/51.65            NR                 NR                  8

  Xia, L., et al. (2012)           22613004   Hepatocellular cancer                     406           NR                    331/75   I-III   201/105           41.89/75.52        27.14/54.28        NR                  8

  Xu, N., et al. (2013)            23536876   Lung cancer                               175           NR                    122/53   I-IV    112/63            37.58/84.19        27.1/73.1          NR                  8

  Yang, D. K., et al. (2009)       19121844   Lung cancer                               69            62(43-84)             65/4     I-III   26/43             51.3/76.84         32.14/76.65        NR                  9

  Yu, J., et al. (2011)            21325289   Malignant peripheral nerve sheath tumor   82            NR                    NR       NR      34/48             20.51/56.2         13.68/40.81        7.28/28.91          6

  Zhao, F., et al. (2014)          25411964   Ovarian cancer                            119           NR                    NR       I-IV    53/29             76.36/81.56        58.44/77.4         35.58/77.4          6
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

FOXM1: Forkhead Box M1; 1: Cohort 1; 2: Cohort 2; 3: Cohort 3; C: cytoplasmic expression; N: nuclear expression; OS: Overall survival.

Association of FOXM1 with OS {#s2_3}
----------------------------

The combined analysis of 23 studies showed that FOXM1 overexpression in tumor tissue was associated with worse 3-year OS (OR = 3.30, 95% CI = 2.56 to 4.25, *P* \< 0.00001), 5-year OS (OR = 3.35, 95% CI = 2.64 to 4.26, *P* \< 0.00001) and 10-year OS (OR = 5.24, 95% CI = 2.61 to 10.52, *P* \< 0.00001) of solid tumors (Figure [2](#F2){ref-type="fig"}). Results of 8 studies showed that FOXM1 expression was associated with statistically significant poor 3-year DFS (OR = 3.01, 95% CI = 2.21 to 4.12, *P* \< 0.00001), 5-year DFS (OR = 3.22, 95% CI = 2.34 to 4.41, *P* \< 0.00001) and 10-year DFS (OR = 4.41, 95% CI = 1.56 to 12.43, *P* = 0.005) (Figure [3](#F3){ref-type="fig"}).

![Overall survival (OS) according to FOXM1 expression in tumor tissue\
**A**. 3-year OS; **B**. 5-year OS; **B**. 10-year OS. C: cytoplasmic expression; N: nuclear expression.](oncotarget-08-32298-g002){#F2}

![Disease free survival (DFS) according to FOXM1 expression in tumor tissue\
**A**. 3-year DFS; **B**. 5-year DFS; **B**. 10-year DFS.](oncotarget-08-32298-g003){#F3}

In the stratified analysis by tumor types, FOXM1 expression was associated with worse 3-year OS of colorectal cancer (OR = 2.56, 95% CI = 1.40 to 4.69, *P* = 0.002), gastric cancer (OR = 2.85, 95% CI = 1.36 to 5.99, *P* = 0.006), hepatic cancer (OR = 5.04, 95% CI = 3.17 to 8.02, *P* \< 0.00001), lung cancer (OR = 5.51, 95% CI = 2.98 to 10.19, *P* \< 0.00001) and ovarian cancer (OR = 2.34, 95% CI = 1.30 to 4.20, *P* = 0.005) (Figure [4](#F4){ref-type="fig"}). Consistent with this 3-year OS, FOXM1 expression was associated with worse 5-year OS of gastric cancer (OR = 3.98, 95% CI = 1.74 to 9.12, *P* = 0.001), hepatic cancer (OR = 3.32, 95% CI = 2.22 to 4.95, *P* \< 0.00001), lung cancer (OR = 8.27, 95% CI = 4.86 to 14.05, *P* \< 0.00001) and ovarian cancer (OR = 3.33, 95% CI = 1.80 to 6.15, *P* = 0.0001) (Figure [5](#F5){ref-type="fig"}). There was no significant association between FOXM1 expression and survival of esophageal cancer and pancreatic cancer ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

![Subgroup analysis of 3-year OS according to FOXM1 expression in different tumor types\
**A**. colorectal cancer; **B**. gastric cancer; **C**. hepatic cancer; **D**. lung cancer; **E**. ovarian cancer.](oncotarget-08-32298-g004){#F4}

![Subgroup analysis of 5-year OS according to FOXM1 expression in different tumor types\
**A**. gastric cancer; **B**. hepatic cancer; **C**. lung cancer; **D**. ovarian cancer.](oncotarget-08-32298-g005){#F5}

We also evaluated the correlation between FOXM1 expression and the TNM stage of tumor. High expression level of FOXM1 was significantly associated with advanced TNM stage (OR = 2.78, 95% CI = 1.64 to 4.71, *P* = 0.0002) (Figure [6](#F6){ref-type="fig"}). Moreover, we found that FOXM1 overexpression in tumor tissue was also significantly correlated with the 3-year OS (OR = 2.62, 95% CI = 1.62 to 4.26, *P* \< 0.0001) and 5-year OS (OR = 3.12, 95% CI = 1.56 to 6.28, *P* = 0.001) of patients with cancer in early stage ([Supplementary Figure 2](#SD1){ref-type="supplementary-material"}).

![Correlation of FOXM1 expression and tumor stage\
C: cytoplasmic expression; N: nuclear expression.](oncotarget-08-32298-g006){#F6}

Meta-regression analysis showed that publication year, country, gender and NOS score did not contribute to the heterogeneity (data not shown).

Sensitivity analyses {#s2_4}
--------------------

Removal of the studies that was an outlier (score, IRS, \> 50%) or no report (NR) with regard to the cutoff of FOXM1 overexpression did not influence results for 3- or 5-year OS (OR = 3.79, 95% CI = 2.89 to 4.97, *P* \< 0.00001; OR = 3.19, 95% CI = 2.54 to 4.01, *P* \< 0.00001; respectively). Exclusion of these studies did not reduce heterogeneity for 3- or 5-year OS (Cochran\'s Q *P* = 0.10, I^2^ = 31%; Cochran\'s Q *P* = 0.24, I^2^ = 19%, respectively).

Removal of studies with NOS score 6 did not influence results for 3- or 5-year OS (OR = 3.57, 95% CI = 2.70 to 4.72, *P* \< 0.00001; OR = 3.32, 95% CI = 2.56 to 4.30, *P* \< 0.00001, respectively). Exclusion of these studies did not reduce heterogeneity for 3- or 5-year OS (Cochran\'s Q *P* = 0.07, I^2^ = 37%; Cochran\'s Q *P* = 0.08, I^2^ = 35%, respectively).

Publication bias {#s2_5}
----------------

Funnel plot analysis showed that there was no statistical evidence of publication bias in our meta-analysis (data not shown).

DISCUSSION {#s3}
==========

This meta-analysis is the most comprehensive assessment of the literatures regarding FOXM1-protein expression and tumor prognosis to date. We systematically evaluated survival data for 2847 solid tumor patients included in 23 different studies. Our study demonstrated that the expression of FOXM1 is a potential biomarker of poor prognosis in most solid tumors, with consistent results of both OS and DFS at 3, 5 and 10 years. Regarding to the tumor types, elevated FOXM1 expression in tumor tissues were associated with worse OS of most human solid tumors, such as colorectal cancer, gastric cancer, hepatic cancer, lung cancer and ovarian cancer. But FOXM1 expression is not statistical correlation with survival of esophageal cancer and pancreatic cancer. In addition, we found expression level of FOXM1 was significantly associated with advanced stage of human solid tumors. And FOXM1 overexpression in tumor tissue is also correlated with unfavorable outcome in early stage cancers.

FOXM1 is a key transcription factor, which provides a balanced transcriptional programme to ensure proper growth and maturation during embryogenesis and foetal development as well as to manage appropriate homeostasis and repair of adult tissues \[[@R32]\]. However, deregulated FOXM1 signalling in cancer is involved in cell migration \[[@R33], [@R34]\], invasion \[[@R35], [@R36]\], angiogenesis \[[@R37], [@R38]\], stem cell renewal \[[@R39], [@R40]\], DNA damage repair and cellular senescence \[[@R41], [@R42]\], which impact tumor initiation \[[@R43], [@R44]\], progression, metastasis, angiogenesis and drug resistance \[[@R45]\]. These evidences suggest that dysregulated of FOXM1 expression and FOXM1 signal pathway in tumor microenvironment may serve as a key factor in human cancer development.

Recently, a comprehensive genomics-based study included 18,000 patients demonstrated that elevated FOXM1 gene expression is correlated with adverse outcome across 39 malignancies \[[@R3]\]. Consistently, our meta-analysis found overexpression of FOXM1 in protein level is also significantly correlated with poor outcome of human solid tumors. These evidences highlight the potential of FOXM1 to be a valuable therapeutic target and prognostic biomarker for solid tumor.

In summary, FOXM1 expression in solid tumor tissues is associated with poor survival in most solid tumors, which suggests that FOXM1 is a valuable prognostic biomarker and a promising therapeutic target for solid tumors.

MATERIALS AND METHODS {#s4}
=====================

This meta-analysis was conducted according to the statement for reporting systematic reviews and meta-analyses \[[@R46]\]. This study summarized and analyzed the results of previous studies, so the ethical approval was not necessary.

Search strategy and study selection {#s4_1}
-----------------------------------

An electronic search of Pubmed and Web of Science were undertaken for studies evaluating FOXM1 expression and clinical outcome in solid tumors from 1994 to June 2016. The search was performed with subject heading terms including "FOXM1 protein, human" and "Neoplasms" and the results were limited to human studies of solid tumors. A total of 310 and 366 entries were identified, respectively. Inclusion criteria were the measurement of FOXM1 expression in tumor tissues by immunohistochemistry (IHC), availability of survival data for at least 3 years, and original article written in English. Citation lists of retrieved articles were manually screened to ensure sensitivity of the search strategy. Study selection was based on the association of FOXM1 expression and survival. Two reviewers (Lijun Li and Dang Wu) evaluated independently all of the full articles for study eligibility. Inter-reviewer agreement was assessed using Cohen\'s kappa coefficient. Disagreement was resolved by consensus.

Data extraction {#s4_2}
---------------

Overall survival (OS) and disease free survival (DFS) were the primary endpoints of interest. Data were extracted using predefined abstraction forms. The following details were extracted by two authors (Lijun Li and Dang Wu): name of first author, year of publication, country of publication, tumor type, patient number, tumor stage, antibodies used for the evaluation, method and score for FOXM1 assessment, and cut-off values to determine FOXM1 positivity. Data for 3, 5 and 10 year of OS and DFS were extracted from tables or Kaplan-Meier curves for both FOXM1 negative and FOXM1 positive group.

The studies included in our meta-analysis were all cohort studies. Two independent authors evaluated the quality of each included study using Newcastle-Ottawa Scale (NOS) \[[@R47]\]. The studies with 6 scores or more were considered as high quality studies. A consensus NOS score for each item was achieved finally.

Data synthesis {#s4_3}
--------------

The relative frequency of OS and DFS at 3, 5 and 10 years between FOXM1 negative and FOXM1 positive group was presented as an odds ratio (OR) and its 95% confidence interval (CI). Sensitivity analyses were carried out for different analytical methods and cut-offs for defining FOXM1 expression and NOS scores for quality assessment of included studies. Publication bias was assessed by visual inspection of the funnel plot.

Statistical analysis {#s4_4}
--------------------

Data were extracted from the primary publications and combined into a meta-analysis using RevMan 5.3 analysis software (Cochrane Collaboration, Copenhagen, Denmark). Estimates of ORs were weighted and pooled using the Mantel-Haenszel random effect model. Statistical heterogeneity was assessed using the Cochran\'s Q and I^2^ statistics. Differences between subgroups were assessed using methods as previous described by Deeks et al \[[@R48]\]. Meta-regression analysis was conducted using Stata 12.0 software (StataCorp LP, College Station, TX). All statistical tests were two-sided, and statistical significance was defined as *P* \< 0.05. No correction was made for multiple statistical testing.
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